Skip to main content
Erschienen in: Drugs & Aging 8/2012

01.08.2012 | Original Research Article

Inappropriate Prescribing of Proton Pump Inhibitors in Older Patients

Effects of an Educational Strategy

verfasst von: Hanifat Hamzat, Hao Sun, Joanna C. Ford, Joan MacLeod, Roy L. Soiza, Professor Arduino A. Mangoni

Erschienen in: Drugs & Aging | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

An increasing number of older patients are prescribed proton pump inhibitors (PPIs). However, the extent of inappropriate PPI prescribing in this group is largely unknown.

Objective

We sought to identify clinical and demographic factors associated with inappropriate PPI prescribing in older patients and to assess the effects of a targeted educational strategy in a controlled hospital environment.

Methods

Clinical and demographic characteristics and full medication exposure on admission were recorded in 440 consecutive older patients (mean ± SD age 84 ± 7 years) admitted to a teaching hospital between 1 February 2011 and 30 June 2011. A 4-week educational strategy to reduce inappropriate PPI prescribing during hospital stay, either by stopping or reducing PPI doses, was conducted within the study period. The main outcome measures of the study were the incidence of inappropriate PPI prescribing and the effects of interventions to reduce it.

Results

On admission, PPIs were established therapy in 164 patients (37%). This was considered inappropriate in 100 patients (61%). Lower Charlson Comorbidity Index score (odds ratio [OR] 0.76; 95% CI 0.57, 0.94; p = 0.006) and history of dementia (OR 1.65; 95% CI 1.28, 1.83; p = 0.005) were independently associated with inappropriate PPI prescribing. Interventions to reduce inappropriate PPI prescribing occurred more frequently during and after the education phase (frequency of interventions in patients with inappropriate PPI prescribing: pre-education phase 9%, during education phase 43%, and post-education phase 46%, p=0.006). Prescribing interventions were not associated with acid rebound symptoms.

Conclusions

Inappropriate PPI prescribing in older patients is frequent and independently associated with co-morbidities and dementia. A targeted inhospital educational strategy can significantly and safely reduce inappropriate PPI prescribing in the short term.
Literatur
1.
Zurück zum Zitat Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64 (10): 935–51.PubMedCrossRef Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64 (10): 935–51.PubMedCrossRef
2.
Zurück zum Zitat Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010; 19 (10): 1019–24.PubMedCrossRef Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010; 19 (10): 1019–24.PubMedCrossRef
3.
Zurück zum Zitat Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1. Int J Clin Pharmacol Ther 2003; 41 (5): 207–12.PubMed Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1. Int J Clin Pharmacol Ther 2003; 41 (5): 207–12.PubMed
4.
Zurück zum Zitat Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12 (8): 797–805.PubMedCrossRef Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12 (8): 797–805.PubMedCrossRef
5.
Zurück zum Zitat Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317 (7156): 452–6.PubMedCrossRef Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317 (7156): 452–6.PubMedCrossRef
6.
Zurück zum Zitat Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008; 336 (7634): 2–3.PubMedCrossRef Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008; 336 (7634): 2–3.PubMedCrossRef
7.
Zurück zum Zitat Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56 (4): 931–50.PubMedCrossRef Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56 (4): 931–50.PubMedCrossRef
8.
Zurück zum Zitat McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26 (6): 624–31.PubMedCrossRef McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26 (6): 624–31.PubMedCrossRef
9.
Zurück zum Zitat Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122 (10): 896–903.PubMedCrossRef Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122 (10): 896–903.PubMedCrossRef
10.
Zurück zum Zitat Jackson SH, Mangoni AA, Batty GM. Optimization of drug prescribing. Br J Clin Pharmacol 2004; 57 (3): 231–6.PubMedCrossRef Jackson SH, Mangoni AA, Batty GM. Optimization of drug prescribing. Br J Clin Pharmacol 2004; 57 (3): 231–6.PubMedCrossRef
11.
Zurück zum Zitat Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57 (1): 6–14.PubMedCrossRef Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57 (1): 6–14.PubMedCrossRef
12.
Zurück zum Zitat Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137 (1): 80–7, 87.PubMedCrossRef Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137 (1): 80–7, 87.PubMedCrossRef
13.
Zurück zum Zitat Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010; 105 (7): 1531–7.PubMedCrossRef Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010; 105 (7): 1531–7.PubMedCrossRef
14.
Zurück zum Zitat Jones MI, Greenfield SM, Jowett S, et al. Proton pump inhibitors: a study of GPs’ prescribing. Fam Pract 2001; 18 (3): 333–8.PubMedCrossRef Jones MI, Greenfield SM, Jowett S, et al. Proton pump inhibitors: a study of GPs’ prescribing. Fam Pract 2001; 18 (3): 333–8.PubMedCrossRef
15.
Zurück zum Zitat de GV, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56 (3): 221–9.PubMedCrossRef de GV, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56 (3): 221–9.PubMedCrossRef
16.
Zurück zum Zitat Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4: 94.PubMedCrossRef Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4: 94.PubMedCrossRef
17.
Zurück zum Zitat Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 2008; 14 (8): 1149–55.PubMedCrossRef Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 2008; 14 (8): 1149–55.PubMedCrossRef
18.
Zurück zum Zitat Proton pump inhibitors. In: British Medical Association and the Royal Pharmaceutical Society. British national formulary. 61st ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2011. Proton pump inhibitors. In: British Medical Association and the Royal Pharmaceutical Society. British national formulary. 61st ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2011.
19.
Zurück zum Zitat National Institute of Clinical Excellence (NICE). Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NICE Technology Appraisal Guidance No. 7. London: NICE, 2000. National Institute of Clinical Excellence (NICE). Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NICE Technology Appraisal Guidance No. 7. London: NICE, 2000.
20.
Zurück zum Zitat Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22 (2): 205–10.PubMedCrossRef Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22 (2): 205–10.PubMedCrossRef
21.
Zurück zum Zitat Shrestha K, Hughes JD, Lee YP, et al. The prevalence of co-administration of clopidogrel and proton pump inhibitors. Qual Prim Care 2011; 19 (1): 35–42.PubMed Shrestha K, Hughes JD, Lee YP, et al. The prevalence of co-administration of clopidogrel and proton pump inhibitors. Qual Prim Care 2011; 19 (1): 35–42.PubMed
22.
Zurück zum Zitat van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in the Netherlands. Pharm World Sci 2002; 24 (3): 100–3.PubMedCrossRef van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in the Netherlands. Pharm World Sci 2002; 24 (3): 100–3.PubMedCrossRef
23.
Zurück zum Zitat Ntaios G, Chatzinikolaou A, Kaiafa G, et al. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 2009; 20 (2): 171–3.PubMedCrossRef Ntaios G, Chatzinikolaou A, Kaiafa G, et al. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 2009; 20 (2): 171–3.PubMedCrossRef
24.
Zurück zum Zitat Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999; 94 (1): 75–9.PubMedCrossRef Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999; 94 (1): 75–9.PubMedCrossRef
25.
Zurück zum Zitat Wayman J, Hayes N, Raimes SA, et al. Prescription of proton pump inhibitors before endoscopy: a potential cause of missed diagnosis of early gastric cancers. Arch Fam Med 2000; 9 (4): 385–8.PubMedCrossRef Wayman J, Hayes N, Raimes SA, et al. Prescription of proton pump inhibitors before endoscopy: a potential cause of missed diagnosis of early gastric cancers. Arch Fam Med 2000; 9 (4): 385–8.PubMedCrossRef
26.
Zurück zum Zitat Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25 (5): 333–40.PubMedCrossRef Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25 (5): 333–40.PubMedCrossRef
27.
Zurück zum Zitat Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000; 46 (4): 464–7.PubMedCrossRef Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000; 46 (4): 464–7.PubMedCrossRef
28.
Zurück zum Zitat Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA 2000; 283 (24): 3230–5.PubMedCrossRef Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA 2000; 283 (24): 3230–5.PubMedCrossRef
29.
Zurück zum Zitat Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004; 19 (8): 917–22.PubMedCrossRef Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004; 19 (8): 917–22.PubMedCrossRef
30.
Zurück zum Zitat Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83 (975): 66–8.PubMedCrossRef Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83 (975): 66–8.PubMedCrossRef
31.
Zurück zum Zitat van Vliet EP, Steyerberg EW, Otten HJ, et al. The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther 2009; 29 (2): 213–21.PubMedCrossRef van Vliet EP, Steyerberg EW, Otten HJ, et al. The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther 2009; 29 (2): 213–21.PubMedCrossRef
32.
Zurück zum Zitat Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39 (5): 649–53.PubMedCrossRef Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39 (5): 649–53.PubMedCrossRef
33.
Zurück zum Zitat Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13 (2): 145–53.PubMedCrossRef Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13 (2): 145–53.PubMedCrossRef
34.
Zurück zum Zitat Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001; 33 (3): 206–9.PubMedCrossRef Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001; 33 (3): 206–9.PubMedCrossRef
35.
Zurück zum Zitat Howden CW, Kahrilas PJ. Editorial: just how “difficult” is it to withdraw PPI treatment? Am J Gastroenterol 2010; 105 (7): 1538–40.PubMedCrossRef Howden CW, Kahrilas PJ. Editorial: just how “difficult” is it to withdraw PPI treatment? Am J Gastroenterol 2010; 105 (7): 1538–40.PubMedCrossRef
36.
Zurück zum Zitat Ishihara M, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol 2002; 444 (3): 209–15.PubMedCrossRef Ishihara M, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol 2002; 444 (3): 209–15.PubMedCrossRef
37.
Zurück zum Zitat Khalil T, Singh P, Fujimura M, et al. Effect of aging on gastric acid secretion, serum gastrin, and antral gastrin content in rats. Dig Dis Sci 1988; 33 (12): 1544–8.PubMedCrossRef Khalil T, Singh P, Fujimura M, et al. Effect of aging on gastric acid secretion, serum gastrin, and antral gastrin content in rats. Dig Dis Sci 1988; 33 (12): 1544–8.PubMedCrossRef
Metadaten
Titel
Inappropriate Prescribing of Proton Pump Inhibitors in Older Patients
Effects of an Educational Strategy
verfasst von
Hanifat Hamzat
Hao Sun
Joanna C. Ford
Joan MacLeod
Roy L. Soiza
Professor Arduino A. Mangoni
Publikationsdatum
01.08.2012
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 8/2012
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/BF03262283

Weitere Artikel der Ausgabe 8/2012

Drugs & Aging 8/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.